Background Despite vitamin K antagonists (VKA) being the gold standard in the prevention
of thromboembolic events in antiphospholipid syndrome (APS), non-vitamin K antagonists …

Background This systematic overview was commissioned by England's Department of
Health and Social Care (DHSC) to assess the evidence on direct (previously 'novel') oral …

Background: Since non-vitamin K antagonist oral anticoagulants (NOACs) do not require
coagulation monitoring, concerns of lower adherence and persistence to NOACs than …

Aims Adherence to guideline-directed oral anticoagulation (OAC) in patients with atrial
fibrillation (AF) improves outcomes, but limited data are available from China. We evaluated …

Background Thromboembolic events are a common complicated health problem. Although
anticoagulants have several positive effects on these conditions, they also have several …

Oral anticoagulation significantly reduces the incidence of dementia in atrial fibrillation
patients. However, this protective effect has not been compared between Direct Oral …

Aim Non-vitamin K antagonist oral anticoagulants (NOACs) were developed as an
alternative to warfarin to prevent thromboembolism in patients with atrial fibrillation (AF) …

Background: Falls are always a concern regarding the balance of risk/benefit in patients with
atrial fibrillation treated with anticoagulants. In this analysis, we aimed to evaluate the …

Oral anticoagulation (OAC) is commonly used to prevent or treat thromboembolic events in
patients with conditions such as atrial fibrillation (AF) and venous thromboembolism (VTE) …

Antiphospholipid syndrome (APS) is an autoimmune disorder that causes venous, arterial
and small-vessel thrombosis, pregnancy loss, and premature birth. Cardiac valvular …